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A recombinant replication-defective adenovirus vector that can overexpress the ectodomain of the envelope
protein of dengue virus type 2 (NGC strain) has been constructed. This virus was immunogenic in mice and
elicited dengue virus type 2 specific B- and T-cell responses. Sera from immunized mice contained neutralizing
antibodies that could specifically recognize dengue virus type 2 and neutralize its infectivity in vitro, indicating
that this approach has the potential to confer protective immunity. In vitro stimulation of splenocytes (from
immunized mice) with dengue virus type 2 resulted in a significant proliferative response accompanied by the
production of high levels of gamma interferon but did not show significant changes in interleukin-4 levels. This
is suggestive of a Th1-like response (considered to be important in the maturation of cytotoxic T lymphocytes
that are essential for the elimination of virus-infected cells). The data show that adenovirus vectors offer a
promising alternative strategy for the development of dengue virus vaccines.
Dengue viruses, which are members of the Flaviviridae fam-
ily, are mosquito-borne human pathogens with a worldwide
prevalence (12). There are four antigenically distinct serotypes
of dengue viruses (28). There is neither an effective antiviral
therapy for the treatment of dengue virus infections nor a
licensed vaccine for their prevention (12, 27). Infection with
any one dengue virus serotype provides lifelong homologous
immunity with only transient cross-protection against the re-
maining three serotypes (19). Sequential infection in areas of
hyperendemicity (where multiple serotypes cocirculate) has
the potential to trigger life-threatening disease widely believed
to be mediated by an antibody-dependent enhancement mech-
anism (33). This has prompted the view that a dengue vaccine
must be tetravalent; that is, it must afford solid and long-lasting
protection against all four dengue virus serotypes.
Several laboratories worldwide are exploring multiple ap-
proaches towards developing dengue virus vaccines based on
live attenuated viruses (1, 21, 36), inactivated viruses (35),
infectious clone-derived intertypic (18, 26) and chimeric (5, 13,
14, 43) viruses, antigen-encoding plasmids (23, 24), recombi-
nant proteins expressed in heterologous systems (2, 22, 38, 40),
and live vaccinia virus vectors encoding antigen genes (9, 31,
32). However, the major focus is on the live, empirically atten-
uated (1, 21, 36), and infectious clone-derived ChimeriVax
vaccines based on the attenuated YF17D yellow fever vaccine
vector (13, 14). Alternative attenuated vector backbones based
on dengue type 1 (DEN-1) (29, 45), DEN-2 (18), and DEN-4
(8) viruses are being developed in parallel. All these strategies
rely on the creation of monovalent vaccine viruses, which are
mixed together to generate tetravalent formulations.
Recent studies in which the tetravalent live attenuated (21)
and ChimeriVax (13) vaccines were tested in humans and
nonhuman primates, respectively, revealed that the tetravalent
formulations elicited an unbalanced immune response, which
was predominantly specific to a single serotype. This has been
ascribed to viral interference that apparently comes into play
when all four vaccine viruses are mixed together and coinjected
(21). The observation that the tetravalent ChimeriVax vaccine
formulation is also apparently associated with the phenome-
non of viral interference (despite all four of its component
viruses having identical YF17D backbones, unlike the live at-
tenuated tetravalent vaccine) underscores the difficulties, and
more importantly the risk, inherent in the current strategy of
creating a tetravalent dengue vaccine. This warrants investiga-
tion of other recombinant viral vector systems that may permit
the creation of a single tetravalent dengue virus vaccine vector.
From such a perspective, the adenovirus (Ad) expression sys-
tem appears worth investigating, as vectors are available that
can accommodate inserts of up to 35 kb (16, 44), making it
possible to envisage the creation of a single vaccine vector that
encodes critical protective antigens of all four dengue virus
serotypes to provide complete protection against dengue.
Ad vectors offer several important advantages from a vac-
cine perspective (reviewed in references 34 and 39). They have
an exceptional safety record as live viral vaccines (10) and are
not particularly pathogenic in humans (17). Two of the most
promising recent reports pertaining to nonhuman primate
models of the Ebola virus (41) and the human immunodefi-
ciency virus (4, 37) emphasize the potential of Ad-based vac-
cination strategy. However, one concern regarding Ad vectors
for human use is that preexisting immunity to Ad can compro-
mise the efficacy of Ad-based vaccines. Recent work on Ad-
based human immunodeficiency virus (4) and Ebola vaccines
(46) has suggested that DNA priming followed by vector boost-
ing can effectively overcome the effect of prior Ad immunity.
Though poxvirus vectors can accommodate very large inserts, a
comparison of attenuated poxvirus vectors such as NYVAC
(11) and MVA (4, 37) with replication-defective Ad vectors
have shown the latter to be safer and more efficacious for
vaccine applications, particularly with reference to the primer-
booster injection strategy.
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To investigate the utility of the Ad vector in developing
dengue virus vaccines, in this study we constructed a replica-
tion-defective recombinant Ad (rAd) vector by inserting the
envelope (E) protein-encoding gene of DEN-2 virus into the
early region 1 (E1) of the Ad genome. The E protein, which is
exposed on the surface of the virus, is the dominant virus
antigen (25) that interacts with host cell receptors (6) and
represents the major target of neutralizing antibodies (7, 30).
We used the ectodomain of the DEN-2E virus molecule ob-
tained by deletion of the carboxy-terminal transmembrane do-
main. This truncation does not compromise the structural-
antigenic integrity of the E protein. In fact, studies have shown
that the truncated version is more immunogenic than the full-
length molecule (32). We also included in our construct the
putative secretory signal encoded by the carboxy terminus of
the premembrane protein. It was necessary to include this
signal sequence, as its deletion inhibited expression of the E
protein (our unpublished data).
The E protein-encoding gene (DEN-2E virus gene) was iso-
lated as a 1.3-kb cDNA fragment by reverse transcription-
PCR using DEN-2 virus (NGC strain) genomic RNA as the
template. The cloned gene was sequenced and verified by com-
parison with published data (20) to correspond to the carboxy-
terminal 31-amino-acid-encoding portion (putative secretory
signal sequence) of the premembrane gene followed by the
amino-terminal 395-amino-acid-encoding portion (the ectodo-
main) of the E gene. The DEN-2E virus gene was placed under
the transcriptional control of the cytomegalovirus (CMV) early
promoter/enhancer in an appropriate shuttle vector, and the
resultant expression cassette was then inserted into the E1
region of the Ad type 5 (Ad5) genome by using in vivo recom-
bination in Escherichia coli and rescuing the resultant E1-
FIG. 1. rAd vector rAdD2E for the expression of DEN-2 virus E protein in mammalian cells. (A) Schematic representation of the linear
genome of rAdDen2E. E1 denotes early region 1 of the Ad genome, which had been replaced by the E ectodomain expression cassette (CMV,
CMV promoter/enhancer; D2E, cDNA encoding the E ectodomain of DEN-2 virus; pA, polyadenylation signal) in the recombinant virus. E3
indicates a 2.7-kb deletion in the nonessential E3 region of the Ad genome. The gray-shaded boxes at either end of the viral genome represent
the cis-acting elements critical for viral DNA replication (L-ITR and R-ITR, left and right inverted terminal repeats, respectively; , packaging
signal). (B) Immunoprecipitation (using DEN-2 virus-specific 3H5 mAb) of DEN-2E virus protein from infected BHK cells. Cells were either mock
infected (lane 1) or infected with cAd (lane 2), rAdD2E (rAd; lane 3), or DEN-2 virus (lane 4). Infected cells were metabolically labeled with
[35S]methionine, lysed, immunoprecipitated with 3H5 mAb, and analyzed on a denaturing 15% polyacrylamide gel. The positions and sizes (in
kilodaltons) of prestained protein markers run on the same gel are indicated on the left of the panel. The arrows on the right indicate the positions
of the full-length E protein expressed by DEN-2 virus (dotted arrow) and the C-terminally truncated version (E ectodomain) expressed by the rAd
vector (solid arrow). (C) Indirect immunofluorescence micrograph of infected BHK cells. Cells were either mock infected or infected with the same
viruses as described for panel B, fixed in cold acetone, and incubated with 3H5 mAb followed by fluorescein-labeled anti-mouse antibody to
visualize E protein expression.
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lacking recombinant virus, rAdD2E, in the E1 trans-comple-
menting human 293 cell line as described previously (15). The
genome structure of rAdD2E (verified by PCR and extensive
restriction analyses) is depicted in Fig. 1A.
We examined the ability of this rAd to express DEN-2E
virus protein in cultured mammalian cells. In the experiment
shown in Fig. 1B, baby hamster kidney (BHK) cells were in-
fected with rAdD2E, control Ad (cAd) (insertless Ad lacking
E1), or DEN-2 virus and metabolically labeled with [35S]me-
thionine. Lysates prepared from these cells were immunopre-
cipitated with 3H5 (42), the DEN-2E virus protein-specific
monoclonal antibody (mAb), and analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. The 3H5 mAb spe-
cifically immunoprecipitated one major protein of the pre-
dicted size (53 kDa) from rAdD2E-infected cells (Fig. 1B,
lane 3). The positive-control experiment carried out in parallel
showed that DEN-2 virus-infected BHK cells expressed the
full-length E protein (Fig. 1B, lane 4). We obtained similar
results using COS cells in place of BHK cells. Interestingly,
when we used 293 and HeLa cells, we detected the expression
of rAd-encoded E ectodomain protein but not of DEN-2 virus-
encoded full-length E protein (data not shown), presumably
reflecting the inability of DEN-2 virus to successfully infect
these cell types.
From a comparison of the expression levels attained (Fig.
1B; compare lanes 3 and 4), it is evident that rAdD2E can be
used to achieve high levels of DEN-2E virus expression in
infected cells. Using a purified preparation of recombinant E
protein mutant containing the 3H5 epitope as a reference in a
quantitative immunoblot assay, we estimated the levels of rAd-
mediated E protein expression in infected BHK cells to be 2
g/106 cells; in 293 cells, the levels were 8- to 10-fold higher
(data not shown). Protein expression was also analyzed by
immunofluorescence, as shown in Fig. 1C. Infected BHK cells
were fixed in acetone and probed with 3H5 mAb. Antigen-
antibody interactions were detected using fluorescein-tagged
anti-mouse immunoglobulin G. Mock-infected as well as cAd-
infected BHK cells failed to show any fluorescence in this
assay. DEN-2 virus-infected BHK cells displayed intense fluo-
rescence and served as the positive control. The rAdD2E-
infected BHK cells manifested fluorescence comparable to
that of the positive control. Interestingly, the difference in E
protein expression levels evident in the immunoprecipitation
experiment was not discernible in the immunofluorescence
experiment. As the same antibody (3H5 mAb) was used in
both techniques, the apparent discrepancy may be a reflection
of differences in the detection methodologies.
Next, we investigated the immunogenicity of the rAd vector.
Groups of six BALB/c mice were immunized intraperitoneally
with rAdD2E or cAd (107 PFU/mouse) at 0, 1, and 2 months.
Sera (collected 1 week after each inoculation) were analyzed
by enzyme-linked immunosorbent assays (ELISA) using live
DEN-2 virus as the capture antigen. The data are depicted in
Fig. 2. Sera collected after the initial injection had no signifi-
cant antibody titers in either cAd- or rAdD2E-immunized an-
imals. However, the presence of DEN-2 virus-specific antibod-
ies could be discerned in the rAdD2E-immunized sera after
the second injection; the levels detected increased quite signif-
icantly after the final injection (Fig. 2B). There was no change
in the observed ELISA titers of cAd-immunized (Fig. 2A) or
phosphate-buffered saline (PBS) (mock)-immunized (data not
shown) mice after the second and third inoculations. The
rAdD2E-induced antibodies specifically recognized the
DEN-2 virus-expressed full-length E protein, as is evident from
the data presented in Fig. 3. In this experiment, culture super-
natants of DEN-2 virus-infected, [35S]methionine-labeled COS
cells were immunoprecipitated with mouse immune sera col-
lected after the first, second, and third immunizations. A con-
trol immunoprecipitation carried out in parallel using 3H5
mAb in place of mouse sera revealed the full-length E protein
FIG. 2. Anti-DEN-2 virus antibodies in rAd-immunized mouse sera. Groups of BALB/c mice (n  6) were immunized intraperitoneally with
either cAd (A) or rAdD2E (B) as described in the text. Anti-DEN-2 virus antibody titers in sera obtained after the first (triangles), second (circles),
and third (squares) injections were determined with DEN-2 virus as the capture antigen and revealed with horseradish peroxidase-conjugated
anti-mouse antibody. ELISA plates (96 well) coated overnight with DEN-2 virus (250 50% tissue culture infective doses [TCID50]) at 4°C were
blocked (in 1 PBS–1% polyvinylpyrrolidone–0.2% horse serum for 2 to 4 h at 4°C), washed four times (using 1 PBS–0.1% Tween 20), and
incubated for 45 min at 37°C with serial twofold dilutions of the individual mouse serum samples. The wells were washed (using 1 PBS–0.25%
Tween 20) and incubated with anti-mouse immunoglobulin G-horseradish peroxidase conjugate (at a 1:5,000 dilution) for 45 min at 37°C, washed
again, and incubated with 3,35,5tetramethyl benzidine substrate for 25 min at 37°C. The color reaction was terminated by the addition of 1 M
H2SO4, and the optical density (OD) was read at 450 nm. Each data point represents the average of six independent determinations (error bars
represent standard deviations [SD]).
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(Fig. 3, lane 2). The rAdD2E-immunized animals did not show
any discernible anti-DEN-2 virus antibody response after the
initial injection (Fig. 3, lane 5). However, after the booster
immunizations an anti-DEN-2 antibody response was readily
detectable in rAdD2E-immunized mouse sera (Fig. 3, lanes 8
and 11). The immunoprecipitated protein bands shown in
lanes 8 and 11 comigrated with the 3H5 immunoprecipitated
band shown in lane 2, indicating that the antibodies elicited by
rAdD2E can efficiently recognize and immunoprecipitate the
full-length E protein expressed by DEN-2 virus.
To determine whether the antibodies induced by rAdD2E
vaccination could neutralize DEN-2 virus infectivity, BHK cells
in 96-well plates were infected with DEN-2 virus preincubated
with twofold serial dilutions of heat (56°C for 30 min)-inacti-
vated immune sera collected after each of the three vaccina-
tions. Simultaneously, we also analyzed immune sera collected
from animals that were immunized with a commercially avail-
able preparation of inactivated DEN-2 virus antigen. As the
rAd vector used here is replication defective (i.e., lacking E1),
we reasoned that it would be appropriate to compare its ca-
pacity to induce neutralizing antibodies with that of inactivated
DEN-2 (iDEN-2) virus rather than with that of replication-
competent live DEN-2 virus. The results are summarized in
Table 1. It is evident from the data that at least one booster
injection is necessary before virus-neutralizing antibodies can
be detected in the sera of rAdD2E-immunized animals. This is
consistent with the ELISA (Fig. 2) and immunoprecipitation
(Fig. 3) data. Sera from the iDEN-2 virus-immunized animals
also failed to manifest detectable neutralizing antibody titers
after the initial injection. After a single booster immunization,
the rAd vector elicited virus-neutralizing antibody titers com-
parable to those elicited by iDEN-2 virus. A second booster
immunization with rAdD2E was accompanied by an increase
FIG. 3. Analysis of rAdD2E-induced DEN-2 virus-specific antibodies in murine sera by radioimmunoprecipitation. Pooled sera (5 l from each
group) obtained from PBS (lanes 3, 6, and 9)-, cAd (lanes 4, 7, and 10)-, and rAd (lanes 5, 8, and 11)-immunized mice collected after the first (A),
second (B), and third (C) vaccinations were incubated separately (overnight at 4°C) with 500 l of DEN-2 virus-infected, [35S]methionine-
radiolabeled COS cell culture supernatant. The resultant antigen-antibody complexes were captured using protein G Sepharose, washed, and
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. A control immunoprecipitation using 3H5 mAb (1 l) instead of murine
antiserum (lane 2) was performed in parallel. Lane 1 shows prestained markers whose positions were traced with radioactive ink on the dried gel
prior to autoradiography. The sizes of these markers are indicated (in kilodaltons) on the left side of the panel. The arrows on the right side of
each panel indicate the positions of the DEN-2 virus-expressed full-length E protein.
TABLE 1. Virus-neutralizing antibody titers in sera of
immunized micea
Immunization
Virus used for immunization (titer)
Noneb cAdc rAdd iDEN-2e
First NDf ND ND ND
Second ND ND 17 15
Third ND ND 73 106
a Aliquots of DEN-2 virus (250 TCID50) were preincubated with serial dilu-
tions of heat-inactivated, pooled antisera and then used to infect BHK cells in
96-well plates (5 wells were assayed for each dilution of antiserum). The anti-
serum dilution corresponding to the 50% end points of virus infectivity was
determined by cumulative averaging using the method of Reed and Muench as
described by Burleson et al. (3); the reciprocal of this dilution is expressed as the
neutralizing titer.
b Mock immunization with PBS.
c cAd lacking E1 (does not encode any dengue virus antigen).
d rAdD2E (rAd lacking E1 and expressing DEN-2E virus protein).
e Formalin-inactivated DEN-2 virus (from Biodesign International).
f ND, No detectable virus-neutralizing antibody titer.
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in virus-neutralizing titers (from 17 to 73). This increase was
comparable to that elicited by iDEN-2 virus after the second
booster inoculation (from 15 to 106). The increases in neutral-
izing antibody titers accompanying the second booster inocu-
lation in the two groups were within 1.5-fold of each other
(73 versus 106). These data demonstrate that the rAdD2E is
immunogenic and can elicit antibodies that can specifically
recognize and neutralize DEN-2 virus.
In addition to neutralizing antibodies, T-cell responses to
dengue viruses are likely to be important in conferring protec-
FIG. 4. Determination of T-cell proliferative response. Splenocytes obtained from cAd-primed (A) and rAd-primed (B) mice were seeded in
96-well plates in Dulbecco’s modified Eagle’s medium–10% heat-inactivated fetal calf serum (2.5  105 cells in 0.1 ml/well). Cells were either mock
stimulated (solid bars) or stimulated with live DEN-2 virus (hatched bars) (at several dilutions as indicated) for 5 days (U, undiluted virus
equivalent to 1,000 TCID50). Each dilution was assayed in triplicate. Cells were pulsed with [
3H]thymidine (1Ci/well) for 16 h at the end of the
5-day incubation period, and proliferation was quantitated by measuring the uptake of the radioisotope in a scintillation counter. Data depicted
represent the mean values of three determinations (error bars represent SD).
FIG. 5. IFN-	 and IL-4 responses to DEN-2 virus stimulation. Splenocytes obtained from cAd-primed (A and C) and rAd-primed (B and D)
mice were either mock stimulated (solid bars) or stimulated with 1000 TCID50 of live DEN-2 virus (hatched bars) for 5 days. Aliquots of the culture
supernatant were withdrawn at the time points shown, and the levels of IFN-	 (A and B) and IL-4 (C and D) were determined by solid-phase
ELISA using commercially available murine IFN-	 and IL-4 kits (Quantikine M; R&D systems). Data depicted represent the mean values of three
separate determinations (error bars represent SD).
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tive immunity. To analyze T-cell response, spleen cells in cul-
ture (derived from cAd- and rAdD2E-primed mice) were re-
stimulated with serial twofold dilutions of DEN-2 virus and
monitored for proliferation responses and cytokine (gamma
interferon [IFN-	] and interleukin-4 [IL-4]) production. At all
dilutions of DEN-2 virus used for in vitro restimulation, cAd-
primed mouse splenocytes did not exhibit any proliferative
response (Fig. 4A). In contrast, cells from rAdD2E-primed
mouse spleens demonstrated a significant proliferation re-
sponse (as evidenced by the magnitude of [3H]thymidine up-
take) at all dilutions of DEN-2 virus used for in vitro restimu-
lation (Fig. 4; compare panels B and A). Mock-stimulated
spleen cell cultures, obtained from rAdD2E-primed mice, dis-
played a consistently minimal response (Fig. 4B). The prolif-
erative response displayed by rAdD2E-primed mouse spleno-
cytes was accompanied by IFN-	 secretion. These cells
displayed significantly elevated levels of IFN-	 after 5 days of
restimulation with DEN-2 virus; mock-stimulated cells did not
secrete IFN-	 into the culture medium (Fig. 5B). When cAd-
primed mouse spleen cell cultures were tested, IFN-	 was
barely detectable in mock- and DEN-2 virus-stimulated culture
supernatants (Fig. 5A). In contrast to the situation with IFN-	,
IL-4 was detected in the splenocyte culture supernatants dur-
ing the entire course of the 5-day experiment. However, there
were only marginal differences in the levels of secreted IL-4
between mock- and DEN-2 virus-stimulated spleen cell cul-
tures regardless of whether they had been obtained from cAd-
or rAdD2E-primed animals (Fig. 5, panels C and D). This
leads to the conclusion that splenocytes from rAdD2E-primed
mice respond to in vitro restimulation with DEN-2 virus by
secreting elevated levels of IFN-	 without any significant
change in the basal levels of IL-4 production. This may be
indicative of a Th1 response, which is considered to be crucial
for maturation of cytotoxic T lymphocytes that are necessary to
eliminate virus-infected cells.
In conclusion, our data show that the rAd vector expressing
the ectodomain of DEN-2E virus protein is immunogenic in
mice and is capable of inducing both B- and T-cell responses.
This is the first report describing the use of a rAd vector as a
possible dengue virus vaccine carrier. The Ad vector used in
this work lacks early regions E1 and E3 and has an insert
capacity of 7.5 kb, of which the CMV promoter-driven
DEN-2E virus expression cassette occupies 2.3 kb. A vector
lacking E1/E3/E4 (with an insert capacity of11 kb) which can
be propagated in 911E4 cells is available (15). Also, there are
Ad vectors lacking all viral genes that have a maximum insert
capacity of 35 kb and can be propagated in the presence of
packaging-defective mutant Ad helpers (44). It is thus feasible to
insert the major structural genes of all four of the dengue viruses
into a single rAd vector. This aspect would make a rAd-based
dengue virus vaccine an attractive alternative, especially since this
strategy has the potential to eliminate the phenomenon of viral
interference that tends to skew the immune response predomi-
nantly towards one serotype when the tetravalent vaccine is con-
stituted from four monovalent viral vaccines (13, 21). Currently,
work is under way to develop such a tetravalent rAd vector.
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